TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07827599: A Phase III, Randomized, Double-blinded, Placebo-controlled Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis of Influenza Virus Infection in Chinese Participants

Sponsor: Hoffmann-La Roche · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 325 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$1,878,660

Rescue Site Savings

+$1,252,440

Unlock Full NCT07827599 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07827599 Rescue Dossier →